Aridis pharmaceuticals provides multiple program updates including the addition of a second inhaled antibody to neutralize newly emerging covid-19 mutated variants

Los gatos, calif., feb. 23, 2021 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that it has augmented its inhaled...
ARDS Ratings Summary
ARDS Quant Ranking